Riverhead Capital Management LLC cut its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 35.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 118,730 shares of the medical equipment provider’s stock after selling 64,604 shares during the quarter. Riverhead Capital Management LLC’s holdings in Boston Scientific Corporation were worth $3,291,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of BSX. UBS Asset Management Americas Inc. boosted its position in Boston Scientific Corporation by 9.1% during the first quarter. UBS Asset Management Americas Inc. now owns 3,435,806 shares of the medical equipment provider’s stock worth $85,448,000 after acquiring an additional 286,705 shares during the last quarter. Teza Capital Management LLC purchased a new position in Boston Scientific Corporation during the first quarter worth about $1,856,000. Karp Capital Management Corp purchased a new position in Boston Scientific Corporation during the first quarter worth about $10,290,000. Smith Salley & Associates purchased a new position in Boston Scientific Corporation during the first quarter worth about $268,000. Finally, Sei Investments Co. raised its stake in Boston Scientific Corporation by 0.6% during the first quarter. Sei Investments Co. now owns 5,097,906 shares of the medical equipment provider’s stock worth $126,785,000 after purchasing an additional 29,627 shares during the period. Hedge funds and other institutional investors own 90.52% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Riverhead Capital Management LLC Sells 64,604 Shares of Boston Scientific Corporation (BSX)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/13/riverhead-capital-management-llc-sells-64604-shares-of-boston-scientific-corporation-bsx.html.

Boston Scientific Corporation (NYSE BSX) opened at 28.92 on Wednesday. The firm’s 50-day moving average is $27.09 and its 200 day moving average is $26.43. The firm has a market cap of $39.68 billion, a PE ratio of 51.74 and a beta of 1.09. Boston Scientific Corporation has a 12-month low of $19.67 and a 12-month high of $29.40.

Boston Scientific Corporation (NYSE:BSX) last posted its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.01. The company had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.21 billion. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The business’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.27 earnings per share. Equities research analysts predict that Boston Scientific Corporation will post $1.26 EPS for the current year.

A number of brokerages have commented on BSX. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Boston Scientific Corporation in a research note on Wednesday, August 9th. J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $31.00 target price (up from $27.00) on shares of Boston Scientific Corporation in a research note on Wednesday, June 28th. Cowen and Company reaffirmed a “buy” rating and set a $32.00 target price (up from $31.00) on shares of Boston Scientific Corporation in a research note on Friday, July 28th. Zacks Investment Research raised shares of Boston Scientific Corporation from a “sell” rating to a “hold” rating in a research note on Monday, July 31st. Finally, Jefferies Group LLC reaffirmed a “hold” rating on shares of Boston Scientific Corporation in a research note on Thursday, September 7th. One analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $29.88.

In other news, CFO Daniel J. Brennan sold 92,158 shares of Boston Scientific Corporation stock in a transaction that occurred on Tuesday, July 11th. The shares were sold at an average price of $27.48, for a total transaction of $2,532,501.84. Following the sale, the chief financial officer now owns 235,421 shares in the company, valued at $6,469,369.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Wendy Carruthers sold 12,433 shares of Boston Scientific Corporation stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $26.75, for a total transaction of $332,582.75. The disclosure for this sale can be found here. Insiders have sold 275,257 shares of company stock worth $7,512,394 in the last quarter. Insiders own 0.74% of the company’s stock.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.